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SIRT1 regulates the DNA damage response by de-
acetylating p53, thereby repressing p53 transcrip-
tional output. Here, we demonstrate that the
sorting protein PACS-2 regulates SIRT1-mediated
deacetylation of p53 to modulate the DNA damage
response. PACS-2 knockdown cells failed to effi-
ciently undergo p53-induced cell-cycle arrest in
response to DNA damage. Accordingly, p53 acety-
lation was reduced both in PACS-2 knockdown
cells and thymocytes from Pacs-2/ mice, thereby
blunting induction of the cyclin-dependent kinase
inhibitor p21 (CDKN1A). The SIRT1 inhibitor EX-
527 or SIRT1 knockdown restored p53 acetylation
and p21 induction as well as p21-dependent cell-
cycle arrest in PACS-2 knockdown cells. Traf-
ficking studies revealed that cytoplasmic PACS-2
shuttled to the nucleus, where it interacted with
SIRT1 and repressed SIRT1-mediated p53 deace-
tylation. Correspondingly, in vitro assays demon-
strated that PACS-2 directly inhibited SIRT1-cata-
lyzed p53 deacetylation. Together, these findings
identify PACS-2 as an in vivo mediator of the
SIRT1-p53-p21 axis that modulates the DNA dam-
age response.INTRODUCTION
The tumor suppressor p53 is perhaps the most frequent target
of genetic lesions in human cancer. Following DNA damage,
p53 orchestrates biological fates ranging from growth arrest
to cell death, and the molecular pathways leading to these
various outcomes depend on several factors, including the
level and type of stress as well as the cell and tissue type (Mir-Cell Rezayans et al., 2012; Zilfou and Lowe, 2009). p53 functions as a
sequence-specific transcription factor that drives the transacti-
vation of target genes mediating cell-cycle arrest, senescence,
or apoptosis induced by the intrinsic pathway (Kruse and Gu,
2009). Among the p53 target genes, perhaps the best character-
ized is the cyclin-dependent kinase inhibitor p21, which pro-
motes cell-cycle arrest, supports DNA damage repair, and
impedes apoptosis (Abbas and Dutta, 2009). In addition, p53
integrates the intrinsic apoptotic pathway with the extrinsic
apoptotic pathway triggered by the death ligand TRAIL. Indeed,
tumor cell apoptosis can be increased when TRAIL is combined
with DNA damage-inducing therapies (Ifeadi and Garnett-Ben-
son, 2012).
The transcriptional activity of p53 is critically dependent
on posttranslational modifications, including phosphoryla-
tion and acetylation, which stabilize p53 and enhance its
transactivation functions, respectively (Kruse and Gu, 2009).
Acetylation of p53 is catalyzed predominantly by the histone
acetyltransferase p300 (Gu and Roeder, 1997). Indeed,
stress-induced p53 acetylation significantly correlates with
p53 activation (Kruse and Gu, 2009; Zilfou and Lowe, 2009).
Accordingly, mutation of all major lysine acetylation sites
blocks the ability of p53 to induce p21 and suppress cell pro-
liferation, suggesting that acetylation of p53 is indispensable
for the p53-p21 pathway (Tang et al., 2008). Conversely, the
class III histone deacetylase (HDAC) SIRT1 inhibits p53 tran-
scriptional activation by deacetylating p53 following DNA
damage (Kruse and Gu, 2009). Together, the overall balance
of p300 and SIRT1 activities modulates p53 transcriptional
function.
Although regulation of p53 by modifying enzymes and cofac-
tors has been extensively studied, less is known about the
regulation of SIRT1. Gene expression of SIRT1 can be regu-
lated transcriptionally and posttranscriptionally (Kwon and
Ott, 2008). In addition, SIRT1 deacetylase activity can be
modulated by interaction with cellular proteins (Hasegawa
and Yoshikawa, 2008; Kim et al., 2007, 2008; Liu et al., 2011;
Zhao et al., 2008). Although these studies provide insight intoports 8, 1545–1557, September 11, 2014 ª2014 The Authors 1545
Figure 1. PACS-2-Deficient Cells Have
Reduced p21-Dependent Cell-Cycle Arrest
following DNA Damage
(A) Control (Con) or PACS-2 siRNA-treated
HCT116 WT or p53/ cells were treated with
0.5 mM Dox for 48 hr or 20 ng/ml TRAIL for 5 hr
prior to harvest and analyzed by western blot
(WB). The cleaved caspase-3 antibody detected
19, 17, and 15 kDa forms. Arrow denotes
cleaved poly(ADP ribose) polymerase (PARP). UT,
untreated.
(B) Control (Con) or PACS-2 siRNA-treated
HCT116 cells were treated with 0.5 mM Dox
and analyzed by western blot. Quantification
using AlphaView (ProteinSimple) showed that
after 16 hr Dox treatment, PACS-2 knockdown
reduced p21 by 50%, whereas PUMA and Bax
were less affected (16% and 12% reduction,
respectively).
(C) Control (Con) or PACS-2 siRNA-treated
HCT116 WT (left) or HCT116 p53/ (right)
cells were treated with 0.5 mM Dox (4 hr) and
analyzed by qPCR (normalized to glyceraldehyde
3-phosphate dehydrogenase [GAPDH]). Error bars
represent mean ± SD from three or more inde-
pendent experiments. Statistical significance
was determined using Student’s t test. NS, not
significant.
(D) HCT116 WT cells from (B) were analyzed
for PUMA mRNA by qPCR (normalized to
GAPDH). Error bars represent mean ± SD
from four independent experiments. Statistical
significance was determined using Student’s
t test.
(E) Synchronized control (Con) or PACS-2 siRNA-
treated HCT116 cells were stimulated to reenter
the cell cycle in the presence of 10 mM BrdU,
treated with 0.5 mMDox (24 hr), and processed for
flow cytometry. Results are representative of three
independent experiments.
See also Table S1 and Figures S1 and S2.the regulation of SIRT1, the diversity of SIRT1 substrates in
pathways ranging from DNA damage and cell survival to
glucose and lipid homeostasis suggests that regulation of
SIRT1 activity is complex and likely requires additional cellular
factors (Brooks and Gu, 2009).
Here, we identify the multifunctional sorting protein PACS-
2 as an inhibitor of SIRT1-mediated deacetylation of p53
following DNA damage. PACS-2 was initially identified by its
role in mediating secretory pathway traffic and formation of
contacts between the endoplasmic reticulum and mitochondria
(mitochondria-associated membranes or MAMs) to regulate in-
terorganellar communication and autophagy (Atkins et al.,
2008; Dikeakos et al., 2012; Hamasaki et al., 2013; Ko¨ttgen
et al., 2005; Simmen et al., 2005). In response to TRAIL, how-
ever, PACS-2 switches to a proapoptotic effector that coordi-
nates trafficking steps leading to mitochondria membrane per-
meabilization and activation of executioner caspases (Aslan
et al., 2009; Werneburg et al., 2012). In this study, we show
that, contrary to its role in TRAIL action, PACS-2 responds to
DNA damage by regulating the extent of SIRT1-mediated de-
acetylation of p53 to induce p21-dependent cell-cycle arrest.1546 Cell Reports 8, 1545–1557, September 11, 2014 ª2014 The AuTogether, these findings suggest that PACS-2 is a regulator
of the SIRT1-p53-p21 axis that modulates the DNA damage
response.
RESULTS
PACS-2 Mediates the p53-Dependent Response to
DNA Damage
Previous studies identified an essential role for cytoplasmic
PACS-2 in mediating TRAIL-induced apoptosis (Aslan et al.,
2009; Werneburg et al., 2012). To determine whether this proap-
optotic requirement for PACS-2 extended to DNA damage, we
compared the effect of PACS-2 knockdown on TRAIL- versus
doxorubicin (Dox)-induced apoptosis in HCT116 wild-type
(WT) or isogenic p53/ cells (Figure 1A). As expected, PACS-
2 knockdown blunted TRAIL-induced apoptosis independent
of p53 status. By contrast, PACS-2 knockdown sensitized
HCT116WT cells but not p53/ cells to Dox-induced apoptosis
(Figures 1A and S1A). This effect additionally required the proap-
optotic p53 target PUMA and was also observed using ionizing
radiation (IR; Figures S1B and S1C). These findings suggestthors
distinct roles for PACS-2 in TRAIL- versus p53-mediated
apoptosis.
PACS-2 Regulates p53-Mediated Cell-Cycle Arrest
following DNA Damage
The increased sensitivity of PACS-2-deficient cells to p53- and
PUMA-mediated apoptosis following DNA damage led us to
ask whether PACS-2 knockdown altered induction of p53 target
genes. Analysis by western blot showed that PACS-2 knock-
down reduced the p53-dependent induction of p21 but had little
effect on the proapoptotic targets PUMA or Bax (Figure 1B).
These findings were consistent with quantitative PCR (qPCR)
analysis, which showed that PACS-2 knockdown reduced the
p53-dependent induction of p21 by approximately 40% (Fig-
ure 1C). MDM2 and Noxa were reduced to a lesser extent,
27% and 19%, respectively, whereas there was no significant
reduction in PUMA, Bax, DR5, 14-3-3, or Gadd45a (Figures 1D
and S2A). Similar results were observed in U2OS cells following
IR, demonstrating that this effect of PACS-2 knockdown on p21
induction was not restricted to a single cell line or treatment
(Figure S2B).
The blunted induction of p21 following DNA damage in PACS-
2 knockdown cells led us to test the role of PACS-2 in mediating
DNA damage-induced cell-cycle arrest. As expected, PACS-2
knockdown significantly reduced the percentage of HCT116
WT cells in G0/G1 compared to control cells following treatment
with Dox (Figure 1E; Table S1). Because p21 has well-described
roles in promoting growth arrest and repressing apoptosis
following DNA damage (Mirzayans et al., 2012), we tested
whether the repressed induction of p21 in PACS-2 knockdown
HCT116 WT cells contributed to their increased sensitivity to
DNA damage. Similar to PACS-2 knockdown, p21 knockdown
sensitized HCT116 cells to Dox-induced apoptosis (Figure S2C).
Consistent with this finding, knockdown of PACS-2 in isogenic
HCT116 p21/ cells failed to further sensitize them to Dox-
induced apoptosis compared to control cells (Figure S2D).
Together, these findings suggest that the disparate p53-depen-
dent induction of p21 versus PUMA in PACS-2-depleted cells
resulted in reduced G1 arrest and a corresponding increase in
apoptosis. These findings further suggest that PACS-2 and
p21may participate in a common pathway to promote cell-cycle
arrest.
PACS-2 Regulates the p53-p21 Axis In Vivo following
DNA Damage
Consistent with the results from both HCT116 and U2OS cells,
Pacs-2/ thymocytes contained reduced levels of p21 protein
and mRNA following exposure to IR (Figures 2A and 2B, and
see Figure 1). The predisposition of thymocytes to undergo
apoptosis in response to IR precluded evaluation of cell-cycle ar-
rest. By contrast, p53-mediated p21 induction plays an essential
role inmitigating GI toxicity following IR by inducing cell-cycle ar-
rest to restrict enterocyte migration along the crypt-villus axis
(Komarova et al., 2004; Leibowitz et al., 2011; Li et al., 2005; Sul-
livan et al., 2012). Consistent with these studies, we found that
migration of bromodeoxyuridine-positive (BrdU+) enterocytes
was restricted in WT mice but not Pacs-2/ mice following IR
(Figure 2C).Cell RePACS-2 Modulates p53 Acetylation In Vivo following
DNA Damage
The determination that PACS-2 knockdown repressed p21 in-
duction but had no significant effect on total p53 levels (see Fig-
ures 1B, 2A, and 2D) suggested that PACS-2 might modulate
p53 activation by controlling p53 posttranslational modifications.
Therefore, we analyzed the extent of p53 Lys382 acetylation,
which correlates with p53 activation and p21 induction (Wang
et al., 2008), and p53 Ser15 phosphorylation, which promotes
p53 stabilization and interaction with p300 (Lee et al., 2010), in
control or PACS-2 knockdownHCT116 cells following Dox treat-
ment. Strikingly, PACS-2 knockdown reduced endogenous p53
Lys382 acetylation, but not Ser15 phosphorylation (Figure 2D).
Similar results were obtained in Pacs-2/ thymocytes where
acetylation of p53 Lys379 (equivalent to human p53 Lys382) was
reduced 60%, whereas p53 pSer18 (equivalent to human p53
Ser15) was unaffected (Figure 2A). Additionally, p53 acetylation
and p21 induction were blunted in PACS-2 knockdown cells
following treatment with the MDM2 antagonist, Nutlin-3a, which
triggers p53-dependent induction of p21 independent of DNA
damage (Figure S3; Kumamoto et al., 2008). Together, these
results suggest that PACS-2 mediates induction of a subset of
p53 target genes by controlling p53 acetylation.
PACS-2 Controls the Extent of Acetylated p53 Bound to
the p21 Promoter following DNA Damage
p53 acetylation is a crucial regulatory element controlling trans-
activation of p53 target genes. Therefore, we performed chro-
matin immunoprecipitation (ChIP) to analyze the amount of total
and acetylated p53 bound to the p21 promoter following DNA
damage (Figure 2E). Indeed, PACS-2 knockdown reduced the
extent of acetylated p53, but not total p53, bound to the p21
promoter following DNA damage. These findings suggest that
PACS-2 loss does not impede binding of p53 to target DNA se-
quences but, instead, diminishes the extent to which promoter-
bound p53 is acetylated and, therefore, transcriptionally active.
PACS-2 Traffics to the Nucleus and Interacts with SIRT1
The determination that loss of PACS-2 reduced the level of
acetylated p53 bound to the p21 promoter led us to ask
whether PACS-2 modulates p53 acetylation by interacting with
p300 or SIRT1. Coimmunoprecipitation analyses demonstrated
that PACS-2 interacted with SIRT1 and that the endogenous
SIRT1-PACS-2 interaction was increased following Dox treat-
ment (Figures 3A and 3B).
Whereas SIRT1 deacetylates histones and transcription fac-
tors in the nucleus, PACS function has thus far been studied
solely in the regulation of membrane traffic in the cytoplasm
(Brooks and Gu, 2009; Youker et al., 2009). Inspection of
the PACS-2 sequence, however, revealed multiple candidate
leucine-rich nuclear export signals (NESs; see Figure 7A; la
Cour et al., 2004; Youker et al., 2009). Indeed, treatment with
the nuclear export inhibitor Leptomycin B (LMB) led to nuclear
accumulation of PACS-2 (Figure 3C). Whereas PACS-2 lacks
a predicted nuclear localization signal (NLS), the PACS-2 pa-
ralog, PACS-1, contains a canonical NLS (..VKKTRRKL318..)
and readily distributes between the cytoplasm and nucleus (Fig-
ure 3C; see Discussion). The homologous sequence in PACS-2ports 8, 1545–1557, September 11, 2014 ª2014 The Authors 1547
Figure 2. PACS-2 Modulates p53 Acetylation In Vivo following DNA Damage
(A) Left: thymuses fromWT and Pacs-2/ (/) mice exposed or not to 4.5 Gy IR (6 hr) were analyzed by western blot. In the right panel, Ac-p53 (K379) and total
p53 were quantified using NIH ImageJ from IR-exposed WT or Pacs-2/ mice. Error bars represent mean ± SEM from four mice per condition. Statistical
significance was determined using Student’s t test.
(B) Thymuses fromWT and Pacs-2/ mice exposed to 4.5 Gy IR (6 hr) as indicated were analyzed for p21 induction by qPCR (normalized to GAPDH). Error bars
represent mean ± SEM from four or more mice per condition. Statistical significance was determined using Student’s t test.
(C) Left: small intestines fromWT and Pacs-2/ (/) mice were analyzed by IHC for BrdU 48 hr following labeling and exposure to 15GyWBI as indicated. In the
right panel, the percentage of BrdU+ cells reaching the upper one-fourth of the villus tips per circumference was quantified. Error bars represent mean ± SD.
Statistical significance was determined using Student’s t test. Quantification from untreated mice was not determined because all villus tips from these mice
contained BrdU+ cells.
(D) p53 was immunoprecipitated from Control (Con) or PACS-2 siRNA-treated HCT116 cells treated with 0.5 mM Dox and analyzed by western blot.
(E) Control (Con) or PACS-2 siRNA-treated HCT116 cells treated with 0.5 mM Dox (6 hr) were analyzed by ChIP qPCR for the p21 promoter using antibodies
specific for total p53 (DO-1) or Ac-p53 (K382). Error bars represent mean ± SEM from three independent experiments. Statistical significance was determined
using Student’s t test. NS, not significant.
See also Figure S3.
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Figure 3. PACS-2 Interacts with SIRT1 in the Nucleus
(A) PACS-2-FLAG was immunoprecipitated (IP) from HCT116 cells, and coprecipitating SIRT1-V5 or p300-HA was detected by western blot.
(B) HCT116 cells treated with 0.5 mMDox (3 hr) as indicated were immunoprecipitated with control immunoglobulin G, anti-PACS-2 (left), or anti-SIRT1 (right), and
coprecipitating SIRT1 (left) or PACS-2 (right) was detected by western blot.
(C) Left: U2OS cells expressing EGFP-PACS-1, mCherry-PACS-2, mCherry-PACS-2DNLS, or mCherry C. elegans PACS (T18H9.7a) were treated with 40 nM
LMB (3 hr) and analyzed by deconvolution microscopy. Nuclei were stained with DAPI. In the top-right panel, percent total cellular fluorescent protein signal in the
nucleus was quantified. Error bars represent mean ±SD from >100 cells in 3 independent experiments. Bottom-right panel shows alignment of the predicted NLS
motif (https://www.predictprotein.org) fitting the consensus [PLV]K[RK]x[RK][RK][RK][PL] from hPACS-1 (sprQ6VY07, gir30089916) with hPACS-2 (sprQ86VP3,
gij155029546), mouse PACS-1 (gir54291704), mouse PACS-2 (kkqrrsiv, gir124487181), chicken PACS-2 (gij513196172), zebrafish PACS-2 (gir170172595),
amphioxus PACS (gij229298623), Drosophila PACS (Krt95D, gir24649488) and C. elegans PACS (T18H9.7a, gir373219078). Consensus basic amino acid
doublets are shaded.
(D) HCT116 cells were treated or not with 0.5 mM Dox for 6 hr. PACS-2 in the nuclear (nuc.) and cytoplasmic (cyt.) fractions was detected by western blot. Error
bars represent mean ± SD from three independent experiments. Statistical significance was determined using Student’s t test.
(E) U2OS cells expressing mCherry-PACS-2 or mCherry-PACS-2DNLS were treated with 100 mM etoposide (3 hr) and analyzed by confocal microscopy. Nuclei
were stained with DAPI. In the bottom panel, percent total cellular fluorescent protein signal in the nucleus was quantified. Error bars represent mean ± SD
from >100 cells in 3 independent experiments. Scale bar, 10 mm.
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Figure 4. PACS-2 Regulates SIRT1-Mediated Deacetylation of p53
In Vivo
(A) Control (Con) or PACS-2 siRNA-treated HCT116 cells were treated with
0.5 mM Dox (6 hr) alone or with 0.5 mM TSA or 1 mM EX-527 and analyzed by
western blot.
(B) Control (Con) or PACS-2 siRNA-treated HCT116 cells were treated as in (A);
total p53 immunoprecipitated with anti-p53 (DO-1) and Ac-p53 (K382) or total
p53 (FL-393) was detected by western blot.
(C) HCT116 cells transfected with control (Con), PACS-2, or SIRT1 siRNAs
were processed as in (B).
1550 Cell Reports 8, 1545–1557, September 11, 2014 ª2014 The Au(..PKKQRRSI239..), when mutated (RR237/AA, hereafter called
PACS-2DNLS), was unaffected by LMB, suggesting that this
motif is required for nuclear localization of PACS-2 (Figure 3C).
PACS sequence alignment suggests that nuclear-trafficking
motifs appeared later in evolution because C. elegans PACS
lacks a predicted NLS and failed to accumulate in the nucleus
(Figure 3C). Treatment with Dox or etoposide increased nuclear
localization of PACS-2, suggesting that a fraction of PACS-2
enters the nucleus to regulate SIRT1 following DNAdamage (Fig-
ures 3D and 3E). The reduced nuclear accumulation of mCherry-
PACS-2 in response to DNA damage compared to LMB may
reflect differences in the signaling pathways that control nuclear
accumulation in response to DNA damage compared to a phar-
macologic block of CRM1-dependent nuclear export.
PACS-2 Regulates SIRT1-Mediated Deacetylation of
p53 to Induce p21-Dependent Cell-Cycle Arrest
The reduced acetylation of p53 in PACS-2-deficient cells
following DNA damage together with the DNA damage-induced
interaction between PACS-2 and SIRT1 (Figures 1, 2, and 3) led
us to ask whether PACS-2 mediates p21 induction by regulating
SIRT1-dependent deacetylation of p53. Accordingly, control or
PACS-2 knockdown HCT116 cells were treated with Dox in the
absenceor presence of the class I/class II HDAC inhibitor trichos-
tatin A (TSA), which does not inhibit the class III HDAC SIRT1, or
with theSIRT1-specific inhibitor EX-527 (Napper et al., 2005; Sol-
omon et al., 2006). As expected (see Figures 1 and 2), PACS-2
knockdown reduced Dox-mediated induction of p21, and this ef-
fect was abrogated by EX-527, but not TSA (Figure 4A), suggest-
ing that the reduced p21 expression in PACS-2-depleted cells
was SIRT1 dependent. Moreover, in agreement with others, the
reduced p53 acetylation in PACS-2-depleted cells was reversed
by EX-527 or the concomitant knockdown of SIRT1 (Figures 4B
and 4C; seeCheng et al., 2003; Solomon et al., 2006). Themolec-
ular basis underlying the ability of TSA to rescue p53 acetylation
but not p21 induction is not known but is consistent with previous
studies (Cheng et al., 2003).
The SIRT1-dependent repression of p53 acetylation and p21
expression in PACS-2 knockdown cells suggested that the sub-
sequent reduction in p21-dependent cell-cycle arrest (see Fig-
ure 1E) might similarly be SIRT1 dependent. Indeed, treatment
of PACS-2 knockdown cells with EX-527 restored p21-depen-
dent cell-cycle arrest and p21 expression (Figures 5A–5C; Table
S2). Importantly, the effect of SIRT1 inhibition was dependent on
PACS-2 knockdown because both the extent of p21 induction
and G1 arrest were not significantly affected by EX-527 in control
cells. Moreover, EX-527 failed to increase the extent of G1 arrest
in p21 knockdown cells, demonstrating that the cell-cycle arrest
rescued by the SIRT1 inhibitor in PACS-2 knockdown cells was
p21 dependent. Together, these data suggest that PACS-2 reg-
ulates the ability of SIRT1 to deacetylate p53 following DNA
damage, thereby promoting p21 induction and p21-dependent
cell-cycle arrest.
PACS-2 Inhibits SIRT1-Mediated Deacetylation of p53
The SIRT1-dependent reduction of acetylated p53 and thus p21
expression in PACS-2-deficient cells suggested that PACS-
2 promotes p53 activation by regulating SIRT1 deacetylasethors
Figure 5. Inhibition of SIRT1 Restores p21-Dependent Cell-Cycle Arrest in PACS-2 Knockdown Cells
(A) Synchronized control (Con), PACS-2, or p21 siRNA-treated HCT116 cells were stimulated to reenter the cell cycle with 10% FBS in the presence of 10 mM
BrdU and then treated or not with 0.5 mMDox (24 hr) in the presence or absence of 10 mMEX-527 and processed for flow cytometry. Results are representative of
three independent experiments.
(B) Quantitation of cells from (A) arrested in G0/G1. Error bars represent mean ±SEM from three independent experiments. Statistical significancewas determined
using Student’s t test. NS, not significant.
(C) Lysates from (A) were analyzed for the indicated proteins by western blot.
See also Table S2.
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Figure 6. Nuclear PACS-2 Regulates the p53-SIRT1 Interaction
(A) Total p53 was immunoprecipitated from HCT116 cells, and Ac-p53 (K382)
was analyzed by western blot.
(B) Endogenous SIRT1 was immunoprecipitated from HCT116 WT or p53/
cells treated with 0.5 mM Dox (6 hr) as indicated, and coprecipitating p53 was
analyzed by western blot.
(C) HCT116 cells were treated with 0.5 mMDox (14 hr), and endogenous SIRT1
immunoprecipitated and coprecipitating p53 were analyzed by western blot.
p53 was quantified using AlphaView (ProteinSimple).activity. Consistent with this possibility, PACS-2, but not PACS-
2DNLS or PACS-1, inhibited SIRT1-dependent p53 deacetyla-
tion (Figure 6A). Interestingly, PACS-2, but not PACS-2DNLS
or PACS-1, blocked the DNA damage-induced interaction
between endogenous SIRT1 and p53 (Figure 6B), whereas1552 Cell Reports 8, 1545–1557, September 11, 2014 ª2014 The Auknockdown of PACS-2 increased the interaction (Figure 6C).
Together, these studies suggest that following DNA damage,
PACS-2 localizes to the nucleus where it regulates the interac-
tion between SIRT1 and p53 to promote p53 acetylation.
Next, we tested whether PACS-2 could bind SIRT1 and
directly inhibit SIRT1-mediated deacetylation of p53 in vitro.
We found that SIRT1 bound specifically to the PACS-2
cargo(furin)-binding region (PACS-2FBR, Figure 7A). Conversely,
the PACS-2FBR preferentially bound the SIRT1 N-terminal region
(NT; Figure 7B) but interacted weakly with a catalytically active
SIRT1 construct lacking the NT (SIRT1-DNT, Figure S4A; see
Experimental Procedures). Importantly, PACS-2FBR inhibited
the ability of full-length SIRT1, but not SIRT1-DNT, to deacety-
late p53 in a nicotinamide adenine dinucleotide (NAD+)- and
dose-dependent manner (Figure 7C). Moreover, full-length
PACS-2 bound SIRT1, but not the p53 substrate, and inhibited
the ability of SIRT1 to deacetylate p53 in vitro (Figures 7D,
S4B, and S4C). By contrast, full-length PACS-1, which also
bound SIRT1, had no measurable effect on SIRT1 activity (see
Figure 6). Together, these results suggest that PACS-2 regulates
p53-mediated p21 induction following DNA damage by control-
ling SIRT1-mediated deacetylation of p53.
DISCUSSION
The balance between cytostasis and apoptosis is a key determi-
nant of cell fate following DNA damage. The selective repression
of p53-mediated p21 induction shifts the DNA damage re-
sponse from cytostasis to PUMA-dependent apoptosis (Haupt
et al., 2003; Seoane et al., 2002). Whereas the most well-charac-
terized role of p21 is the execution of p53-dependent cell-cycle
arrest, p21 also directly antagonizes PUMA- and Bax-mediated
apoptosis by preventing procaspase-3 activation and by re-
pressing procaspase-2 expression (Baptiste-Okoh et al., 2008;
Hill et al., 2011; Suzuki et al., 2000; Yu et al., 2003). Thus, our
determination that following DNA damage PACS-2 knockdown
cells have repressed induction of p21 but not PUMA or Bax, as
well as increased apoptosis, suggests that PACS-2 inhibits
SIRT1 to selectively promote p21-dependent cytoprotective
functions of the p53-dependent DNA damage response.
SIRT1 is frequently reported to delay aging by promoting
cell survival (Brooks and Gu, 2009; Cheng et al., 2003; Cohen
et al., 2004). Thus, our determination that PACS-2 knock-
down leads to a SIRT1-dependent reduction in p53 acetyla-
tion and p21 expression as well as sensitization of cells to
DNAdamage-induced apoptosis appears inconsistent with a cy-
toprotective role for SIRT1. The well-established antiaging roles
for SIRT1, however, may not necessarily correlate with a cyto-
protective role following DNA damage. Indeed, deletion of
p21 improves stem cell maintenance and increases lifespan,
whereas induction of p21 protects adult stem cells from acute
genotoxic stress but impairs stem cell survival in the context of
age-associated chronic DNA damage (Ju et al., 2007; Mantel
and Broxmeyer, 2008; Sperka et al., 2012). To what extent
these findings in stem cells extend to cancer cells warrants
investigation.
The role of SIRT1 in tumor cell survival and cancer progression
is controversial because SIRT1 has both tumor-promoting andthors
Figure 7. PACS-2 Inhibits SIRT1-Mediated Deacetylation of p53 In Vitro
(A) Top: schematic of hPACS-2 and the predicted NLS (above) and NES (below). In the bottom panel, full-length His6-SIRT1D6-83 was incubated with GST or
GST-PACS-2 constructs, and interacting His6-SIRT1D6-83 was detected by western blot. Captured GST fusion proteins were detected with Ponceau S.
(B) Top: schematic of mSIRT1. In the bottom panel, His6-PACS-2FBR was incubated with GST or GST-SIRT1 constructs, and interacting His6-PACS-2FBR was
detected by western blot as in (A).
(C) GST-Ac-p53 (see Experimental Procedures) was incubated with 0.5 mM NAD+ and His6-tagged SIRT1 or SIRT1-DNT together with increasing amounts of
His6-PACS-2FBR as indicated. The amount of Ac-p53 (K382) was quantified and presented as percent acetylation. Error bars represent mean ± SEM from four
independent experiments.
(D) GST-Ac-p53 was incubated with 0.5 mM NAD+ and His6-SIRT1 together with increasing amounts of His6-PACS-1 or PACS-2 as indicated. The amount of
Ac-p53 (K382) was quantified as in (C).
See also Figure S4.tumor-suppressive functions (Herranz and Serrano, 2010; Roth
and Chen, 2014). These opposing roles for SIRT1 are likely man-
ifest through extensive SIRT1 substrates together with the ability
of SIRT1 to differentially affect the cellular response to chemo-
therapeutics. For example, in cells exposed to high concen-
trations of chemotherapeutics, overexpressed SIRT1 represses
induction of p53 target genes and reduces apoptosis (Luo
et al., 2001; Vaziri et al., 2001). By contrast, and similar to our
findings reported here, viability of HCT116 cells and otherCell Recell lines exposed to therapeutic doses of Dox is reduced by
SIRT1 overexpression or treatment with SIRT1 activators but is
increased by addition of EX-527 (Shin et al., 2014). Together,
these findings suggest that the roles of SIRT1 in the cellular
response to DNA damage are complex and manifest in a dose-
and context-dependent manner.
In contrast to other sirtuin family members, SIRT1 additionally
possesses N- and C-terminal extensions containing autoregula-
tory domains and binding sites for SIRT1 modulators (Hasegawaports 8, 1545–1557, September 11, 2014 ª2014 The Authors 1553
and Yoshikawa, 2008; Kang et al., 2011; Kim et al., 2007, 2008;
Liu et al., 2011; Zhao et al., 2008). The SIRT1 C-terminal exten-
sion contributes to the KM for NAD
+ and contains an autoregula-
tory segment that binds the core domain, which is required for
catalytic activity (Kang et al., 2011; Pan et al., 2012). The
SIRT1 N-terminal extension contributes to kcat and regulates
allosteric binding of sirtuin-activating compounds (Hubbard
et al., 2013). Like PACS-2, the SIRT1 activator AROS binds the
SIRT1 NT but has an opposing role on p53 regulation. Whereas
PACS-2 inhibits SIRT1 to increase p53 acetylation, p21 induc-
tion, and p21-dependent cell-cycle arrest, AROS activates
SIRT1 to decrease p53 deacetylation and consequently blunt
p21 induction and cell-cycle arrest (Kim et al., 2007). By contrast,
DBC1 binds to the SIRT1 catalytic (sirtuin) domain, and, unlike
PACS-2, small interfering RNA (siRNA) knockdown of this inhib-
itor blunts the induction of several proapoptotic p53 targets,
including PUMA, Bax, and Bim, and paradoxically increases in
the cell-cycle inhibitor GADD45a (Kim et al., 2008; Yuan et al.,
2012; Zhao et al., 2008). Correspondingly, DBC1 knockdown
reduces apoptosis, albeit with high concentrations of chemo-
therapeutics. However, the extent to which the cytoprotective
effects of DBC1 knockdown following DNA damage result from
increased SIRT1 versus the selective reduction of proapoptotic
genes warrants further investigation. Moreover, the blunted
acetylation of p53 in Pacs-2/ thymocytes following DNA
damage despite similar expression of DBC1 (Figure 2A) sug-
gests that PACS-2 and DBC1 regulate SIRT1 independently
and have dynamic and concerted roles in resolving the DNA
damage response.
Acetylation-dependent transactivation of p53 involves a
C-terminal cluster of six lysine residues and three additional
sites within the core domain (Brooks and Gu, 2011). p300 acety-
lates the p53 C-terminal cluster, including Lys382, preventing
MDM2-mediated ubiquitylation and promoting p53 transactiva-
tion (Lee et al., 2010; Luo et al., 2004; Tang et al., 2008; Wang
et al., 2008). However, the PACS-2-mediated acetylation of
p53 Lys382 alone cannot explain the requirement for PACS-2
in the expression of a subset of p53 target genes. Interestingly,
the DNA damage-mediated induction of p21 but not Bax addi-
tionally requires recruitment of BRCA1 and CARM1, which
methylates p300 to stabilize the transcriptional complex (Lee
et al., 2011). In contrast to p21, the p53-dependent induction
of proapoptotic PUMA requires Tip60 or MOF-mediated acety-
lation of Lys120 (Sykes et al., 2006; Tang et al., 2006). Because
SIRT1 also regulates these two acetyltransferases, it will be
important to determine whether PACS-2 regulates the action
of SIRT1 against one or both enzymes or whether PACS-2 me-
diates recruitment of BRCA1/CARM1 to induce p21 (Peng et al.,
2012).
Cytoplasmic PACS-2 mediates MAM formation, autophagy,
and protein traffic in the secretory and endocytic pathways (At-
kins et al., 2008; Betz et al., 2013; Dikeakos et al., 2012; Hama-
saki et al., 2013; Ko¨ttgen et al., 2005; Simmen et al., 2005). In
response to TRAIL, PACS-2 switches to a proapoptotic effector
independent of p53 status that coordinates trafficking steps
leading to Bim- and Bid-dependent lysosomal and mitochondria
membrane permeabilization, respectively, to trigger activation
of executioner caspases (Aslan et al., 2009; Werneburg et al.,1554 Cell Reports 8, 1545–1557, September 11, 2014 ª2014 The Au2012). It was therefore surprising that PACS-2 has seemingly
opposing roles in TRAIL-induced versus DNA damage-induced
apoptosis where in response to DNA damage, nuclear PACS-2
promotes p53 transactivation to induce p21-dependent cell-cy-
cle arrest (Figures 4, 5, and 6). Recent studies, however, sug-
gest that TRAIL selectively kills arrested cells (Ehrhardt et al.,
2013). Thus, PACS-2-mediated cell-cycle arrest may enhance
PACS-2-dependent TRAIL-induced apoptosis. Therefore, it will
be important to determine the stoichiometry of nuclear PACS-2
and SIRT1 that promotes p21 induction as well as the extent to
which SIRT1 interaction involves preexisting nuclear PACS-2
versus PACS-2 translocated from the cytoplasm in response to
DNA damage.
Our data identify PACS-2 as a member of an emerging
collection of proteins with established roles in regulating both
secretory pathway traffic and nuclear gene expression (Copley,
2012). Phylogenetic studies indicate that the PACS genes ap-
peared first in metazoans (Youker et al., 2009). Although lower
metazoans express a single PACS gene, separate PACS-1 and
PACS-2 genes are predicted to have arisen in higher metazoans
by gene duplication. Sequence alignment suggests that PACS-1
and PACS-2 underwent evolutionary adaptation with the acqui-
sition of nuclear-trafficking motifs (see Figure 3C). Consistent
with this model, C. elegans PACS failed to accumulate in the
nucleus in LMB-treated cells (Figure 3C). This evolutionary
acquisition of nuclear-trafficking functions parallels the role of
p53 in directing cell-cycle arrest. p53 was found to promote
apoptosis in worms and flies but in higher metazoans was found
to additionally induce p21-dependent cell-cycle arrest (Lu et al.,
2009). These findings raise the possibility that the ability of
PACS-2 to traffic to the nucleus resulted from evolutionary adap-
tation required to support the more complex demands of p53 to
resolve the DNA damage response.
In summary, our data demonstrate that the multifunctional
protein PACS-2 shuttles to the nucleus and directly inhibits
SIRT1-mediated deacetylation of p53, thereby controlling the
SIRT1-p53-p21 axis to modulate the DNA damage response.
Our findings, together with the broad and important role of
SIRT1 in controlling pathways associated with cancer, aging,
and metabolism, suggest that a more complete understanding
of the regulation of SIRT1 is warranted to better understand
the complex role of this deacetylase in controlling homeostasis
and disease.
EXPERIMENTAL PROCEDURES
Experimental Animals
The Oregon Health & Science University (OHSU) Department of Comparative
Medicine and the University of Pittsburgh Division of Laboratory Animal
Resources approved all animal studies. Pacs-2/ mice (Aslan et al., 2009)
were maintained on a C57BL/6 background with more than ten backcrosses.
Mice were irradiated using a J.L. Shepherd & Associates Mark I Model 30 ce-
sium irradiator (1.475 Gy/min) in a Plexiglas pie plate rotating at 7 rpm. Where
indicated, WT and Pacs-2/ mice were injected with 50 mg/kg BrdU and
immediately exposed to 15 Gy whole-body irradiation (WBI). At 48 hr following
labeling, a 3 cm segment of ileum just proximal to the cecum was processed
for immunohistochemistry (IHC) by the OHSU Histopathology Core.
Antibodies, Chemicals, Plasmids, and siRNAs
See Supplemental Experimental Procedures.thors
Cell Harvest and Tissue Processing
HCT116 cell lines (providedwith permission fromB. Vogelstein) and U2OS and
293T cells were cultured in Dulbecco’s modified Eagle’s medium plus 10%
fetal bovine serum (FBS). For most experiments, cells were harvested in modi-
fied radioimmunoprecipitation assay buffer (mRIPA) (50 mM Tris-HCl [pH 8.0]
plus 1% NP-40, 1% deoxycholate, and 150 mM NaCl) containing proteinase
inhibitors (0.5 mM phenylmethanesulfonylfluoride, 0.1 mM each of aprotinin,
E-64, and leupeptin) and phosphatase inhibitors (1 mM Na3VO4 and 20 mM
NaF). For monitoring Ac-p53, cells were harvested in Ac lysis buffer (20 mM
Tris-HCl [pH 7.6] plus 0.5% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM dithio-
threitol [DTT], and 5 mM TSA) containing protease inhibitors and phosphatase
inhibitors. Mouse tissues were homogenized in RIPA (50 mM Tris-HCl [pH 8.0]
plus 150 mM NaCl, 1% NP-40, 1% deoxycholate, and 0.1% SDS) containing
protease/phosphatase inhibitors using a motorized Teflon glass homogenizer.
Protein concentration was determined according to manufacturer’s instruc-
tions (#500-0006; Bio-Rad).
Flow Cytometry Analyses
Flow cytometry was performed on FACSCalibur or Accuri C6 (BD Biosciences)
flow cytometers. Data were analyzed using FCS Express (v.3.0; BD
Biosciences).
Cell-Cycle Analysis
HCT116 cells were nucleofected (Amaxa) on days 0 and 2 with the indicated
siRNAs. On day 4, the nucleofected cells were synchronized by serum depri-
vation (0.1% FBS) for 24 hr and stimulated to reenter the cell cycle by addition
of 10% FBS in the presence of 10 mMBrdU and treated or not with 0.5 mMDox
or 10 mMEX-527 for an additional 24 hr as indicated. EX-527 was used in these
experiments because it could selectively inhibit SIRT1 following serum depri-
vation, thereby avoiding nutrient-affected changes in SIRT1 prior to DNA
damage (Nemoto et al., 2004). Cells were processed according to the manu-
facturer’s instructions (#559619; BD Pharmingen), and flow cytometry was
performed as above.
qPCR Analysis
Cell culture studies were performed using subconfluent HCT116 cells, trans-
fected with siRNAs, synchronized with 1% serum, and refed with 10% serum
in the absence or presence of Dox as indicated. RNAwas isolated according to
manufacturer’s instructions using TRIzol (#15596-026; Sigma-Aldrich) for
mouse tissues and RNeasy (#74104; QIAGEN) for cell culture. RNA was
reverse transcribed using the SuperScript III First-Strand cDNA Synthesis Kit
(#18080-051; Invitrogen). Reactions were performed in a StepOne Real-Time
PCR Systemwith the Power SYBRGreen PCRMaster Mix (#4368706; Applied
Biosystems) using the primer pairs listed in Supplemental Experimental Proce-
dures. All reactions were performed in triplicate.
ChIP Analysis
ChIP experiments were performed according toMahata et al. (2012) with mod-
ifications as detailed in Supplemental Experimental Procedures.
Baculovirus
Full-length human PACS-1 (hPACS-1)- and hPACS-2-coding sequences
containing a C-terminal His tag were subcloned into pVL1392 (BD Biosci-
ences) to create high-titer recombinant baculoviruses (BV:His6-PACS-1 and
BV:His6-PACS-2) in Sf9 insect cells according to the manufacturer’s protocol
(BD Biosciences). Sf9 cells were cultured for 72 hr with BV:His6-PACS-2 or
BV:His6-PACS-1 and dounce homogenized in harvest buffer (50 mM NaHPO4
[pH 7.4] and 300 mM NaCl). Lysates were clarified by centrifugation
(20,000 rpm, 20 min). His6-tagged proteins were purified using Ni
2+-NTA
agarose (QIAGEN) and dialyzed against PBS.
In Vitro Binding
Glutathione S-transferase (GST) proteins were preincubated with Glutathione
Sepharose 4B (GE Healthcare) in binding buffer (20 mM Tris-HCl [pH 7.9],
150 mM NaCl, 0.1% NP-40, 0.1 mM EDTA, and 0.3 mM DTT), mixed with
His6-constructs (30 min, room temperature), washed 33 (20 mM Tris-HCl
[pH 7.9], 300 mM NaCl, 0.1% NP-40, 0.1 mM EDTA, and 3 mM DTT), andCell Reanalyzed by western blot using anti-His6. For SIRT1 and full-length PACS inter-
actions, His6-PACS-1 or His6-PACS-2 expressed in baculovirus-infected Sf9
cells was mixed with GST or GST-SIRT11–737 preincubated with Glutathione
Sepharose 4B and processed as above.
In Vitro Deacetylase Assays
Substrate preparation and in vitro deacetylation assays were performed as
described (Aslan et al., 2009; Kang et al., 2009; Simmen et al., 2005). Briefly,
purified GST-hp53373–385 was acetylated by His6-PCAF352–832 in HAT buffer
(50 mM Tris-HCl [pH 8.0], 10% glycerol, 0.1 mM EDTA, and 1.0 M DTT) with
5mM acetyl coenzyme A (Millipore). For assays with full-length PACS proteins,
purified His6-mSIRT1 was preincubated with GST-Ac-p53 and full-length
His6-PACS-1 or PACS-2 in deacetylase buffer (50 mM Tris-HCl [pH 8.0] plus
150 mM NaCl, 10 mM MgCl2, 1 mM DTT, and protease inhibitors) for
30 min. Assays using PACS-2FBR were conducted in binding buffer (see
above). Reactions were initiated with 0.5 mM NAD+ (Millipore) and run for
1 hr to overnight at 37C.
Microscopy
U2OS cells were transfected (FuGENE 6) with the indicated plasmids, and
images were acquired on a high-resolution, wide-field Core DeltaVision Sys-
tem (Applied Precision) as described (Dikeakos et al., 2012). Nuclear and
cytoplasmic fluorescent signal was determined using softWoRx Explorer
2.0 (Applied Precision) also as described (Dikeakos et al., 2012). Briefly, for
each cell counted, the mCherry or DAPI fluorescent signal was quantified
from a precise region of interest over the nucleus, cytoplasm, and extracel-
lular space. The fluorescent signal in each channel was automatically
captured, and the signal from the extracellular space was subtracted from
the nuclear and cytoplasmic signals. The nuclear signal was then divided
by the total (nuclear plus cytoplasmic) signal. Statistical significance was
determined using a two-sided unpaired Student’s t test with unequal
variance.
Nuclear Fractionation
Cells were harvested in Buffer 1 (50 mM Tris-HCl [pH 7.9] plus 10 mM KCl,
1 mM EDTA, 0.2% NP-40, 10% glycerol, and protease inhibitors) and centri-
fuged (3.3k 3 g, 3 min, 4C). The nuclear pellet was lysed with Buffer 2
(20 mM HEPES [pH 7.9] plus 400 mM NaCl, 10 mM KCl, 1% NP-40, 20%
glycerol, 1 mM EDTA, and protease inhibitors) for 20 min at 4C, then centri-
fuged (16.1k 3 g, 10 min, 4C). Soluble nuclear and cytoplasmic fractions
were immunoprecipitated with anti-FLAG-agarose or anti-SIRT1 (H-300) anti-
bodies, and immune complexes were captured with Protein G Sepharose
(Invitrogen) for 2 hr at 4C, washed 33 in wash buffer (20 mM Tris-HCl [pH
7.6] plus 0.5% NP-40, 150 mM NaCl, and 1 mM EDTA), and eluted in SDS
sample buffer prior to western blot.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.07.049.
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